

## Research Article

# Controversy over Mild Stroke

Zhenhua Li<sup>1</sup> and Junzheng Yang<sup>2\*</sup>

<sup>1</sup>Department of Neurosurgery, Anyang People's Hospital, China

<sup>2</sup>Pharmaceutical Department, Institute of Consun Co. for Chinese Medicine in Kidney Diseases, China

\*Address Correspondence to Junzheng Yang, E-mail: yangjunzheng606403@163.com

Received 07 December, 2021; Accepted 21 December, 2021; Published 28 December, 2021

Copyright © 2021 Zhenhua Li, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

Mild stroke patients are a special and controversial population. Mild stroke patients usually have a naturally good prognosis, and thrombolysis can alleviate the symptoms of mild stroke effectively, but thrombolysis increase the risk of bleeding. If all mild stroke patients are treated with thrombolytic therapy, these patients with good prognosis may bear additional thrombolytic costs and bleeding risk. In fact, 29% of patients did not receive thrombolytic therapy because of slight or rapid improvement of symptoms, resulting in a poor prognosis at 90 days. In the early stage of the disease, the potential severity of mild stroke may be underestimated due to mild symptoms, so as to miss the opportunity of thrombolysis and lead to poor prognosis.

**Keywords:** Mild stroke; Intravenous thrombolytic therapy; Controversy; Prognosis

### Controversy over the Concept of Mild Stroke

After slogan “small stroke, big trouble” was put forward on World Stroke Day in 2008, the research on mild stroke has becoming a hot research topic. However, the definition of mild stroke is difficult, and there is still no unified definition standard. In the currently published guidelines, the definitions of mild symptoms, rapid improvement of symptoms and other common thrombolytic criteria are vague and easy to cause major misunderstandings [1].

In clinical practice, NIHSS score is one of the common stroke evaluation methods. It is found that there are still some limitations in using NIHSS score to define mild stroke:

1. Insufficient evaluation of posterior circulation ischemia
2. Hemispheric bias (the NIHSS score of right hemisphere infarction will be less than that of left hemisphere with the same infarct volume)
3. The total score of NIHSS can be the sum of several sub items with mild neurological deficit, or only a single sub item with severe neurological deficit, which may cause severe disability

4. Unable to evaluate neurological deficits such as cognition and depression
5. Based on clinical neurological deficit symptoms, it does not include imaging information, and cannot reflect whether there is stenosis of extracranial and extracranial vessels, the degree of collateral compensation and cerebral perfusion.

Different studies have different definitions of mild stroke. The inconsistency of the definition of mild stroke may directly lead to the inconsistency and uncertainty of relevant research results.

### Controversy over Intravenous Thrombolytic Therapy for Mild Stroke

Whether thrombolysis can be used in mild stroke is controversial. Scholars who agree with thrombolytic therapy believe that thrombolytic therapy can improve vascular recanalization rate, reduce early disability rate, and is safe and feasible. Scholars who do not agree with thrombolytic therapy believe that there is no significant difference in the outcome of patients with mild stroke, and even thrombolysis will bring a higher risk of bleeding.

At present, the American Heart Association (AHA)/American Stroke Association (ASA) guidelines for the treatment of acute ischemic stroke point out that it is reasonable to consider intravenous thrombolytic therapy in patients with non-disabling mild stroke, and it is recommended to conduct more studies to determine the risk ratio in this population [2]. The Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018 lists mild stroke as the relative contraindication of Tissue plasminogen activator (rt PA) intravenous thrombolysis [3]. The risks and benefits of thrombolysis need to be carefully considered and weighed. Intravenous thrombolysis can be considered on the premise of full evaluation and communication.

The US “get with the guidelines” registration study retro-

spectively analyzed mild stroke patients (NIHSS  $\leq 5$ ) who came to the hospital within 4.5 hours of onset and received rt PA treatment, found that even with thrombolytic therapy, 30% of patients still had a poor prognosis at discharge (unable to walk independently or go home directly) [4]. Meta-analysis results showed that mild stroke patients who received intravenous rt PA, the proportion of patients with poor prognosis was 23.9%. There was no significant difference in 3 month prognosis between mild stroke patients who received intravenous rt PA thrombolytic therapy and mild stroke patients who did not receive rt PA thrombolytic therapy [5]. Another Meta-analysis found that alteplase thrombolysis could improve the prognosis of mild stroke, but significantly increased the probability of symptomatic intracranial hemorrhage [6]. And another article demonstrated that the benefit of intravenous thrombolysis in mild stroke patients (NIHSS  $\leq 5$ ) was not obvious, but it did not increase the incidence of symptomatic intracranial hemorrhage, subgroup analysis of IST-3 trial also showed that rt PA had no significant effect on patients with mild stroke [7,8]. The preliminary results of prisms showed that there was no significant difference in the outcome of thrombolysis or not, but the thrombolytic treatment group had a higher rate of symptomatic intracranial hemorrhage [9].

An analysis based on TIMS-China and China stroke registration study (CNSR) showed that patients with mild stroke who received rt PA had a better prognosis trend than those who do not receive thrombolytic therapy (the proportion of patients with Mrs 0-1 at 3 months was 77.6% vs 69.5%), but the overall difference was not statistically significant. The study also found that intravenous thrombolysis had different effects on the prognosis of different subtypes of mild stroke, and the LAA subgroup benefited more from rt PA than other subgroups [10].

These data suggested that the benefits of intravenous thrombolysis for disabled stroke patients may not be extended to mild stroke patients without obvious disability, and thrombolysis for non-disabled mild stroke patients may be unreasonable.

There are three potential causes for final disability in patients with mild stroke:

1. Initial event: because the definition of mild stroke is inaccurate, it is not accurately identified or the disability is not fully recognized. The disability is the direct result of stroke. Or the early stage of stroke is non-disabled light stroke, then progress to disabling stroke.
2. Stroke recurrence
3. Medical events caused by related comorbidities leading to mild stroke.

## Discussion

### Solution 1

Starting from the definition of mild stroke, explore more appropriate evaluation criteria and treatment options.

The biggest defect of NIHSS score is that it cannot reflect

the degree of perfusion of extracranial and extracranial blood vessels and brain tissue, but it is the key to reperfusion treatment in acute stage. Torres mozqueda et al. proposed to define mild stroke by imaging method (BASIS): there is no large extracranial and extracranial vascular occlusion on CTA or MRA, and there is no obvious infarct on CT or MA Compared with NIHSS and ASPECTS, this classification can better predict the prognosis of mild stroke. It is not only suitable for posterior circulation infarction, but also directly reflect the situation of responsible vessels, and provide a more reasonable basis for ultra-early treatment of mild stroke [11].

Fischer et al. compared six definition methods for mild stroke and pointed out that two of them are most suitable for the diagnosis of mild stroke:

1. Each NIHSS score must be 0 or 1, and each consciousness score must be zero
2. The total baseline NIHSS score is less than 3.

The patients with mild stroke with these two definition methods have the best short term and medium term prognosis [12]. Spokoyny et al. applied the new definition of mild stroke (TREAT derived mild stroke criteria) to evaluate the effect of intravenous thrombolysis. The results suggested that intravenous thrombolysis did not increase the risk of symptomatic intracranial hemorrhage, and patients with mild stroke did not benefit from thrombolysis [13].

In 2016, China's guidelines for the diagnosis and treatment of high risk non-disabling ischemic cerebrovascular events defined mild stroke as any of the following: NIHSS score  $\leq 3$ , NIHSS score  $\leq 5$ , and modified Rankin Scale (MRS) score  $\leq 3$  [14].

The existing definition of mild stroke is gradually improved and closer to the clinic, with the combination of specific NIHSS score, non-disabling clinical symptoms and multimode imaging evaluation. However, these definitions do not consider the length of onset and the dynamic evolution of the disease. Evaluating the severity by the state of the patient at the time of treatment cannot reflect the overall picture of the patient's condition, and still cannot perfectly define the patients with mild stroke.

The ideal concept of mild stroke should have the following clinical characteristics [15]:

1. Mild symptoms without aggravation and good prognosis
2. It is suitable for stroke patients with different etiological subtypes
3. It is simple and practical in clinical practice
4. It does not overlap with transient ischemic attack. Developing an international consensus definition of mild stroke will contribute to the improvement of clinical diagnosis, medical intervention management, appropriate referral and prognosis evaluation of such patients.

## Solution 2

Improve thrombolytic risk and benefit decision making of mild stroke through multimodal imaging evaluation.

Patients with low NIHSS score often do not show obvious disability or show the real face of the disease. Clinicians often underestimate the severity of the disease or mistake similar stroke as stroke when deciding whether to thrombolytic treatment for mild stroke based on clinical symptoms. Imaging examination can more intuitively display the degree, nature, vascular status, collateral compensation, pathophysiological changes and so on, so as to make up for the deficiency of clinical standards.

**Excluded stroke and TIA:** Negative results of DWI may occur in up to 25%-30% of patients with ischemic stroke [16]. 28% of mild stroke patients with NIHSS 0-5 were DWI negative (NIHSS 0: 46%, NIHSS

1. 32%, NIHSS 2: 23%, NIHSS 3: 12%, NIHSS 4: 10%, NIHSS 5: 14%). The lower the NIHSS score, the higher the DWI negative probability. The DWI negative proportion of acute stroke patients with NIHSS 0-2 score is higher than NIHSS 3-5 score. The DWI positive probability of mild stroke patients with ataxia, dysarthria, facial and motor defects is higher. All patients with neglect and visual defects are DWI positive, while patients with sensory disorders are unlikely to have DWI positive performance. Mild stroke patients with motor dysfunction, ataxia and high NIHSS scores, especially those with visual or neglect scores, have a high probability of DWI positive, while patients with simple sensory impairment may be stroke like rather than acute stroke [17]. However, the study did not dynamically track the evolution of DWI and the relationship between the length of onset and the positive rate of DWI. Some patients may have negative DWI due to too short onset time, or TIA rather than acute cerebral infarction.
2. Screening silent type stroke and active type stroke and determining the population benefiting from thrombolysis.

Adequate assessment using multimode imaging techniques may help to distinguish patients at risk of deterioration and disability from patients with a benign natural history and identify markers of reperfusion benefits.

**Infarct location and prognosis:** Subcortical infarction and brainstem infarction are more likely to affect patients' ability of daily living after 3 months [18].

**Infarct volume and prognosis:** Khatri et al. showed a similar correlation in patients with mild stroke (mild stroke defined as NIHSS score less than 5) [1]. Subjects with poor prognosis of mild stroke had larger infarct focus at baseline DWI, and increased infarct focus often occurred, and early neurological deterioration often occurred within 5 days. Early deterioration of nervous system and enlargement of infarct size are associated with poor prognosis. However, there was no significant difference in the incidence of ear-

ly neurological deterioration (NIHSS score increased by  $\geq 2$  points 0-5 days after admission) between patients with NIHSS score of 0-3 and patients with NIHSS score of 4-5 [19].

Final infarct volume (FIV) is a recognized prognostic factor for moderate and severe stroke, and there is a significant correlation between infarct volume and clinical prognosis [20-21]. Recent pilot studies on mild stroke (NIHSS 0-7) have shown that thrombolytic therapy in patients with large infarct size on diffusion weighted imaging (DWI) may reduce the expansion of infarct size [22]. Vagal et al. found that setting the final infarct volume threshold of MRI to 20 mL can distinguish the prognosis of patients with mild stroke. Whether intravenous thrombolytic therapy may improve clinical outcomes by reducing FIV is unclear [23].

**Proximal vascular occlusion and prognosis:** Another factor that may lead to nervous system deterioration and poor prognosis in patients with mild stroke is proximal vascular occlusion (i.e. PAO) [24,25]. PAO patients are more likely to have larger infarct volume. In mild stroke (when DWI lesion is relatively small compared with moderate/severe stroke), the growth of infarct is less frequent and smaller [22,26]. Mair et al. found that 51% of patients without vascular occlusion by MRA/CTA had no obvious thrombolytic effect [27]. Patients with early deterioration of neurological function are often complicated with vascular occlusion [28]. These factors may lead to the negative results of the prisms study, which does not require imaging other than plain CT scan of the head [29].

**Collateral circulation and prognosis:** The relationship between collateral compensation and functional prognosis in patients with moderate and severe stroke has been fully documented, but the role of collateral circulation in mild stroke has not been fully studied [30]. Olivot et al. applied multimode imaging cohort study to show that low perfusion intensity ratio is related to slow infarct growth and small final infarct volume. These imaging features can evaluate the quality of collateral circulation and predict the growth of infarct volume [31]. Brown et al. directly compared the mild stroke group (NIHSS  $\leq 4$  points) with the moderate and severe stroke group (NIHSS  $>4$  points) and evaluated it with multimode images. The results showed that the clinical symptoms of stroke patients without atrial fibrillation were mild in men, small PWI lesion volume, small DWI lesion volume, small mismatch volume (PWI-DWI). In patients with similar occlusive sites, patients with mild symptoms tend to have smaller DWI volume and slower growth rate of early infarction. In addition, no other clinical or baseline imaging features change with symptom severity. It is conceivable that in mild stroke, patients with good collateral compensation may have better tissue perfusion protection and better embolic clearance. Therefore, the infarct volume is small, the risk of nervous system deterioration is low, the natural prognosis is good, and the benefit of intravenous thrombolysis may not be significant [32].

Majidi et al. studied the safety and efficacy of thrombolytic therapy in patients with acute stroke with low NIHSS score

screened by MRI. All patients underwent MRI scans before and 24 hours after thrombolytic therapy, including diffusion weighted imaging (DWI), hemosiderin weighted imaging (SWI), fluid attenuated inversion recovery (FLAIR), time of flight magnetic resonance angiography (MRA), and perfusion weighted imaging (PWI) to identify stroke, macrovascular lesions, the number of microbleeds Compared with thrombolysis after routine CT screening, thrombolysis after MRI multimode image screening has higher good prognosis and lower bleeding rate [33].

It is very important to link the clinical results with the imaging findings. Before making a treatment decision, it may be more helpful to identify the group of mild stroke patients who may have early neurological deterioration and may benefit from ultra-early reperfusion treatment by confirming the infarct volume, whether there is perfusion injury or vascular occlusion, and the advantages and disadvantages of collateral circulation.

### Solution 3

#### Prevent stroke recurrence

The poor prognosis of patients with mild stroke is not necessarily caused by the stroke itself or bleeding transformation. The poor prognosis of 90 days may be due to the disability caused by non-neurological causes during this period (such as falls caused by improper nursing), and more importantly, recurrent stroke.

10%-20% of patients with mild stroke relapse within 3 months [34]. The 2013 CHANCE study showed that aspirin combined with clopidogrel in the acute phase can reduce the recurrence risk and the incidence of disabling recurrence events within 90 days in patients with TIA and mild stroke, do not increase the bleeding risk of patients, and may benefit patients with large atherosclerosis [35]. The 2018 point study once again confirmed the research results of the chase scheme. Compared with the Chinese population included in the chase study, the point study is mainly aimed at the European and American population, and the race is more diverse. The heavy publication of the results of the two studies is of great significance to improve the prognosis of patients with mild stroke, so the guidelines for the treatment of non-disabling stroke have been rewritten [36].

#### Conclusions

At present, the controversy about thrombolysis in the treatment of mild stroke is based on different definitions and different views on the risk/benefit ratio of treatment. If we can ideally identify patients at risk of poor prognosis and give thrombolytic therapy, there may be ideal benefits. These patients include

1. Extracranial and extracranial large vessel occlusion
2. Diffusion weighted MR imaging in acute phase showed relatively large infarct
3. Perfusion imaging showed a large low perfusion area.

#### References

1. P. Khatri, M. R. Conaway, K. C. Johnston, Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke, *Stroke*, 43 (2012), 560-562.
2. W. J. Powers, A. A. Rabinstein, T. Ackerson, 2018 Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association, *Stroke*, 49 (2018), e46-e110.
3. Neurology branch of Chinese Medical Association, cerebrovascular disease group of Neurology branch of Chinese Medical Association, Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018. *Chinese J Neurol*, 51 (2018), 671-672 .
4. J. G. Romano, E. E. Smith, L. Liang, Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get with the Guidelines-Stroke registry. *JAMA Neurol*, 72 (2015), 423-431.
5. L. Shi, M. Zhang, H. Liu, Safety and outcome of thrombolysis in mild stroke: A meta-analysis. *Med Sci Monit*, 20 (2014), 2117-2124.
6. J. Emberson, K. R. Lees, P. Lyden, Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials, *Lancet*, 384 (2014), 1929-1935.
7. L. L. L. Yeo, R. Ho, P. Paliwal, R. Rathakrishnan, V. K. Sharma, Intravenously administered tissue plasminogen activator useful in milder strokes? A meta-analysis, *J Stroke Cerebrovasc Dis*, 23 (2014), 2156-2162.
8. P. Sandercock, J. M. Wardlaw, R. I. Lindley, The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial, *Lancet*, 379 (2012), 2352-2363.
9. S. D. Yeatts, J. P. Broderick, A. Chatterjee, Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design, *Int J Stroke*, 13 (2018), 654-661.
10. W. Chen, Y. Pan, X. Zhao, Intravenous thrombolysis in Chinese patients with different subtype of mild stroke: Thrombolysis in patients with mild stroke, *Sci Rep*, 7 (2017), 2299.
11. F. Torres-Mozqueda, J. He, I. B. Yeh, An acute stroke classification instrument that includes CT or MR angiography The Boston Acute stroke imaging scale (BASIS), *AJNR*, 29 (2008), 1111-1117.

12. U. Fischer, A. Baumgartner, M. Arnold, What is a minor stroke, *Stroke*, 41 (2010), 661-666.
13. I. Spokoyny, R. Raman, K. Ernstrom, Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients, *J Stroke Cerebrovasc Dis*, 24 (2015), 1276-1281.
14. Guidelines compilation group of Chinese Stroke Society, Guidelines for the diagnosis and treatment of high-risk non disabling ischemic cerebral artery events, 2016, *Chinese J Stroke*, 11 (2016), 481-491.
15. S. R. Pamela, K. Shilpa, B. Suzanne, D. Ouellette, R. Monique, Pappadis, MEd. Inconsistent classification of mild stroke and implications of health services delivery, *APMR*, 101 (2020), 1243-1259.
16. F. N. Doubal, M. S. Dennis, J. M. Wardlaw, Characteristics of patients with minor ischaemic strokes and negative MRI: A cross-sectional study, *J Neurol Neurosurg Psych*, 82 (2011), 540-542.
17. S. Yaghi, C. Herber, J. Z. Willey, Itemized NIHSS subsets predict positive MRI strokes in patients with mild deficits, *J Neurol Sci*, 358 (2015), 221-225.
18. C. Lin, R. Sangha, J. Lee, Infarct location is associated with quality of life after mild ischemic stroke, *Int J Stroke*, 13 (2018), 824-831.
19. J. T. Kim, M. S. Park, J. Chang, Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke, *PLoS One*, 8 (2013), e70996.
20. S. F. Zaidi, A. Aghaebrahim, X. Urrea, Final infarct volume is a stronger predictor of outcome than recanalization in patients with proximal middle cerebral artery occlusion treated with endovascular therapy, *Stroke*, 43 (2012), 3238-3244.
21. A. J. Yoo, Z. A. Chaudhry, R. G. Nogueira, Infarct volume is a pivotal biomarker after intra-arterial stroke therapy, *Stroke*, 43 (2012), 1323-1330.
22. K. Villringer, U. Grittner, L. A. Schaafs, IV t-PA influences infarct volume in minor stroke: A pilot study, *PLoS One*, 9 (2014), e110477.
23. A. S. Vagal, H. Sucharew, S. Prabhakaran, Final infarct volume discriminates outcome in mild strokes, *Neuroradiol J*, 28 (2015), 404-408.
24. V. Rajajee, C. Kidwell, S. Starkman, Early MRI and outcomes of untreated patients with mild or improving ischemic stroke, *Neurol*, 67 (2006), 980-984.
25. M. R. Heldner, S. Jung, C. Zubler, Outcome of patients with occlusions of the internal carotid artery or the main stem of the middle cerebral artery with NIHSS score of less than 5: comparison between thrombolysed and non-thrombolysed patients. *J Neurol Neurosurg Psych*, 86 (2015) 755-760.
26. N. Asdaghi, M. D. Hill, J. I. Coulter, Perfusion MR predicts outcome in high-risk transient ischemic attack/minor stroke: A derivation-validation study, *Stroke*, 44 (2013), 2486-2492.
27. G. Mair, R. Von-Kummer, A. Adami, IST-3 Collaborative Group. Arterial obstruction on computed tomographic or magnetic resonance angiography and response to intravenous thrombolytics in ischemic stroke, *Stroke*, 48 (2017), 353-360.
28. S. B. Coutts, J. Modi, S. K. Patel, CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: Results of the prospective CATCH study, *Stroke*, 43 (2012), 1013-1017.
29. P. Khatri, D. O. Kleindorfer, T. Devlin, R. N. Sawyer, M. Starr, et al. PRISMS Investigators, Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: The PRISMS randomized clinical trial, *J American Med Asso*, 320 (2018), 156-166.
30. D. S. Liebeskind, T. A. Tomsick, L. D. Foster, Collaterals at angiography and outcomes in the interventional management of stroke (IMS) III trial, *Stroke*, 45 (2014), 759-764.
31. J. M. Olivot, M. Mlynash, M. Inoue, Hypoperfusion intensity ratio predicts infarct progression and functional outcome in the defuse cohort, *Stroke*, 45 (2014), 1018-1023.
32. T. A. Brown, M. Luby, J. Shah, D. Giannakidis, L. L. Latour, Magnetic Resonance Imaging in Acute Ischemic Stroke Patients with Mild Symptoms: An Opportunity to Standardize Intravenous Thrombolysis, *J Stroke Cerebrovasc Dis*, 24 (2015), 1832-1840.
33. S. Majidi, M. Luby, J. K. Lynch, MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS, *Neurol*, 93 (2019), e1507-e1513.
34. A. Chandratheva, O. C. Geraghty, P. M. Rothwell, Poor performance of current prognostic scores for early risk of recurrence after minor stroke, *Stroke*, 42 (2011), 632-637.
35. W. Yongjun, W. Yilong, Z. Xingquan, Clopidogrel with aspirin in acute minor stroke or transient ischemic attack, *N Eng J Med*, 369 (2013), 11-19.
36. S. C. Johnston, J. D. Easton, M. Farrant, Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA, *N Engl J Med*, 379 (2018), 215-225.